

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Gerard GOUBIN et al.

Entitled: ANTI-OZF PROTEIN MONOCLONAL ANTIBODIES AND THEIR
APPLICATIONS IN THE DIAGNOSTIC AND THERAPEUTIC FIELD

Appl. No.: 09/786,722

Filing Date: March 27, 2001

Examiner: To be assigned

Art Unit: 1614

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.56

Commissioner for Patents
Box PATENT APPLICATION
Washington, D.C. 20231

Sir:

The foregoing document(s) came to Applicant's attention during the prosecution of the corresponding international application. A copy of the International Search Report is attached setting forth the portion of each document considered relevant by the examiner. Copies of the documents are not being provided since copies should have been provided directly by WIPO under an exchange program between the PTO, the EPO and the JPO.

Respectfully submitted,

Date August 29, 2001

FOLEY & LARDNER
3000 K Street, N.W., Suite 500
Washington, D.C. 20007-5109
Telephone: (202) 672-5569
Facsimile: (202) 672-5399

By Philip J. Anticola *Rig. No.*
38,819
for / Stephen B. Maebius
Attorney for Applicant
Registration No. 35,264

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: August 11, 2001 <i>(use as many sheets as necessary)</i>		Complete if Known	
		Application Number	09/786,722
		Filing Date	03/27/2001
		First Named Inventor	Gerard GOUBIN
		Group Art Unit	1614
		Examiner Name	Not yet assigned
Sheet 1 of 1	Attorney Docket Number	065691-0214	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
		D. FERBUS et al., European Journal of Biochemistry, "Identification nuclear localization and binding activities of OZF, a human protein solely composed of zinc-finger motifs," Vol. 236, No. 3, pp. 991-995 (1996) XP002095518	
		C. LE CHALONY et al., Journal of Molecular Biology, "The OZF gene encodes a protein consisting essentially of zinc finger [sic] motifs," Vol. 236, No. 2, pp. 399-404 (1994) XP02095520	
		D. FERBUS et al., International Journal of Cancer, "Amplification and over-expression of OZF, a gene encoding a zinc finger protein, in human pancreatic carcinomas," Vol. 80, No. 3, pp. 369-372 (1999) XP002095519	
		D. FERBUS et al., Hybridoma, "Production and characterization of mouse monoclonal antibodies to human zinc finger OZF protein overexpressed in pancreatic carcinomas," Vol. 18, No. 5, pp. 431-6 (1999) XP002127523	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.